Shah-Jalal Sarker1, Sophia K Smith2, Kashfia Chowdhury1, Patricia A Ganz3, Sheryl Zimmerman4, John Gribben5, Ania Korszun6. 1. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. 2. Cancer Care Research Program, Duke Clinical Research Institute, Durham, USA. 3. UCLA Schools of Medicine and Public Health, Jonsson Comprehensive Cancer Center , Los Angeles, USA. 4. School of Social Work, University of Illinois , Chicago, USA. 5. Centre for Haemato-Oncology, Barts Cancer Institute , Queen Mary University of London, London, UK. 6. Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London,, London, UK. a.korszun@qmul.ac.uk.
Abstract
PURPOSE: The aims of this study were to examine quality of life, using the Impact of Cancer version 2 (IOCv2), in British non-Hodgkin lymphoma (NHL) survivors and investigate differences between survivors in the UK and the USA. METHODS: NHL survivors (326 UK and 667 US) completed the 37-item IOCv2 and psychological distress, fatigue and social support questionnaires. RESULTS: The IOCv2 showed good reliability in the British sample with higher internal consistency (Cronbach alpha 0.7-0.9) and no floor and ceiling effects. UK survivors showed significantly higher negative (p < 0.001) and higher positive (p = 0.003) IOC compared to US survivors. Younger survivors (p = 0.003), those with shorter time since diagnosis (p < 0.001) and with lower levels of social support (p = 0.001), showed more negative IOC in both groups. Higher negative IOC was also significantly associated with fatigue (p < 0.001) and depressive symptoms (p < 0.001) in both countries. Higher positive IOC was associated with female gender (p < 0.001), longer time since diagnosis (p = 0.02), those diagnosed at later stage (p < 0.05) and with greater social support (p = 0.004). Whereas significantly lower positive IOC was associated with white ethnicity (p < 0.001), higher education levels (p < 0.05) and fatigue (p = 0.001). CONCLUSIONS: The IOCv2 is reliable and applicable in UK and US populations. Both negative and positive IOC scores were higher in British compared to US survivors. However, in both countries, psychosocial factors consistently showed the greatest impact on QOL irrespective of clinical characteristics. Recognition and treatment of individuals with these risk factors is a high priority for improving QOL in long-term cancer survivors, as is the development of modular interventions aimed at increasing positive IOC as well as decreasing negative impact. The IOCv2 shows great potential both as a screening and assessment measure for examining cancer-related outcomes among survivors.
PURPOSE: The aims of this study were to examine quality of life, using the Impact of Cancer version 2 (IOCv2), in British non-Hodgkin lymphoma (NHL) survivors and investigate differences between survivors in the UK and the USA. METHODS:NHL survivors (326 UK and 667 US) completed the 37-item IOCv2 and psychological distress, fatigue and social support questionnaires. RESULTS: The IOCv2 showed good reliability in the British sample with higher internal consistency (Cronbach alpha 0.7-0.9) and no floor and ceiling effects. UK survivors showed significantly higher negative (p < 0.001) and higher positive (p = 0.003) IOC compared to US survivors. Younger survivors (p = 0.003), those with shorter time since diagnosis (p < 0.001) and with lower levels of social support (p = 0.001), showed more negative IOC in both groups. Higher negative IOC was also significantly associated with fatigue (p < 0.001) and depressive symptoms (p < 0.001) in both countries. Higher positive IOC was associated with female gender (p < 0.001), longer time since diagnosis (p = 0.02), those diagnosed at later stage (p < 0.05) and with greater social support (p = 0.004). Whereas significantly lower positive IOC was associated with white ethnicity (p < 0.001), higher education levels (p < 0.05) and fatigue (p = 0.001). CONCLUSIONS: The IOCv2 is reliable and applicable in UK and US populations. Both negative and positive IOC scores were higher in British compared to US survivors. However, in both countries, psychosocial factors consistently showed the greatest impact on QOL irrespective of clinical characteristics. Recognition and treatment of individuals with these risk factors is a high priority for improving QOL in long-term cancer survivors, as is the development of modular interventions aimed at increasing positive IOC as well as decreasing negative impact. The IOCv2 shows great potential both as a screening and assessment measure for examining cancer-related outcomes among survivors.
Entities:
Keywords:
Cancer survivors; Depression; Impact of cancer scale; Non-Hodgkin lymphoma; Quality of life; Social support
Authors: Pamela H Mitchell; Lynda Powell; James Blumenthal; Jennifer Norten; Gail Ironson; Carol Rogers Pitula; Erika Sivarajan Froelicher; Susan Czajkowski; Marston Youngblood; Marc Huber; Lisa F Berkman Journal: J Cardiopulm Rehabil Date: 2003 Nov-Dec Impact factor: 2.081
Authors: Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet Journal: J Clin Epidemiol Date: 2006-08-24 Impact factor: 6.437
Authors: Sophia K Smith; Sheryl Zimmerman; Christianna S Williams; John S Preisser; Elizabeth C Clipp Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: P A J Vissers; M S Y Thong; F Pouwer; M M J Zanders; J W W Coebergh; L V van de Poll-Franse Journal: J Cancer Surviv Date: 2013-08-06 Impact factor: 4.442
Authors: M M Hawkins; E R Lancashire; D L Winter; C Frobisher; R C Reulen; A J Taylor; M C G Stevens; M Jenney Journal: Pediatr Blood Cancer Date: 2008-05 Impact factor: 3.167
Authors: Liam Bourke; Kate E Homer; Mohamed A Thaha; Liz Steed; Derek J Rosario; Karen A Robb; John M Saxton; Stephanie J C Taylor Journal: Cochrane Database Syst Rev Date: 2013-09-24
Authors: Elisavet Moschopoulou; Jennifer Deane; Morvwen Duncan; Sharif A Ismail; Sophie Moriarty; Shah-Jalal Sarker; Peter White; Ania Korszun Journal: Support Care Cancer Date: 2021-03-30 Impact factor: 3.603